A bipartisan coalition of U.S. Representatives—including Morgan Luttrell (R-TX), Lou Correa (D-CA), Jack Bergman (R-MI), and Michael McCaul (R-TX)—has introduced new federal legislation aimed at formalizing psychedelic research.
The bill, titled the Initiating Biomedical Outcomes to Garner Advancements into Innovative Neuroplastogens (IBOGAIN) Act, seeks to codify an executive order originally issued during the Trump administration that focused on streamlining the research and clinical access pathways for psychedelic medicine. By enshrining these provisions into federal statute, the bill aims to prevent future administrations from easily reversing or deprioritizing the advancement of neuroplastogens, which include substances such as psilocybin and ibogaine. The legislative push reflects a broader shift in federal sentiment regarding non-cannabis botanical and chemical therapies, potentially signaling a more permissive regulatory environment for controlled substances with perceived therapeutic utility.
For stakeholders in the cannabis space, this development underscores the growing synergy between cannabis policy reform and the wider psychedelic research movement. As federal agencies like the FDA face increased pressure to clarify pathways for psychedelic approval, the legislative groundwork for a regulated market—or at least a robust clinical research framework—continues to harden. This bill is expected to face standard legislative hurdles, but its bipartisan backing suggests that neuroplastogen research is gaining traction as a policy priority separate from the more polarized debates surrounding adult-use cannabis reform.